Exelixis (EXEL) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exelixis (EXEL) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 52.7% versus a loss of 4.3%. Over five years, EXEL leads with a +170.5% price change compared with -16.0% for QGEN. Exelixis is the larger company by market cap ($14.62 billion vs $9.20 billion), about 1.6 times the size.
On valuation, Exelixis trades at a lower forward P/E (13.9x vs 17.0x for Qiagen N.V.). Qiagen N.V. pays a dividend yielding 0.82%, while Exelixis does not currently pay one. Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 20.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | QGEN |
|---|---|---|
| Share price | $59.02 | $44.53 |
| Market cap | $14.62B | $9.20B |
| 1-day change | +0.99% | -0.58% |
| YTD return | +34.66% | -0.40% |
| 1-year return | +52.74% | -4.29% |
| 5-year return | +170.49% | -15.95% |
| P/E ratio (TTM) | 18.62 | 22.60 |
| Forward P/E | 13.92 | 17.04 |
| EPS (TTM) | $3.17 | $1.97 |
| Dividend yield | 0.00% | 0.82% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | $2.32B | $2.09B |
| Revenue growth (YoY) | +6.98% | +5.65% |
| Net income (latest FY) | $782.57M | $424.88M |
| Gross margin | 96.39% | 62.18% |
| Operating margin | 37.59% | 22.29% |
| Net margin | 33.73% | 20.33% |
| 52-week high | $61.14 | $57.82 |
| 52-week low | $33.76 | $32.53 |
| Distance from 52-week high | -3.47% | -22.99% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -7.61% | +6.15% |
| Average volume | 2.34M | 2.58M |
| Shares outstanding | 247.78M | 206.50M |
| Employees | 1,077 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed QGEN by 57.0 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 20.3 cents for Qiagen N.V..
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
EXEL vs QGEN FAQ
Which is bigger, Exelixis or Qiagen N.V.?
Exelixis (EXEL) is larger, with a market capitalization of $14.62B compared with $9.20B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, EXEL or QGEN?
EXEL returned +52.74% over the past 12 months, compared with -4.29% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or QGEN?
EXEL has the lower trailing P/E at 18.6, versus 22.6 for QGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Exelixis or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.82%, while Exelixis does not currently pay a regular dividend.
Are Exelixis and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.